SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff across AI neocloud stocks, fueled by concerns about financing costs and whether the sectors business models can deliver returns, has put NBIS in focus. Traders are split between viewing the drop as an overdone, oversold pullbackwith some citing NBISs stronger financial positionand expecting more downside amid lingering sector risks.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy has fueled a rebound discussion after a sharp selloff, with some traders seeing the decline as overdone and others warning that CoreWeaves heavy debt and financing needs remain a risk. The debate centers on whether AI demand and contracted business can outweigh concerns about borrowing costs and the companys ability to fund its expansion.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is drawing attention after stronger-than-expected third-quarter results and a sharply higher 2027 adjusted EBITDA outlook. Bulls are highlighting the improved outlook and potential short-covering, while skeptics question whether operating gains can ease the companys substantial debt burden.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The prolonged wait for the 80th death event in SELLASs blinded Phase 3 REGAL trialand the final analysis of its GPS treatment for AMLis driving attention amid share-price weakness. Bulls interpret the delay and upcoming ASH meeting as possible signs of extended survival or data disclosure, while skeptics say the timeline and CEOs comments prove nothing; no outcome has been confirmed, and traders also watch for SLS009 data.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is drawing attention around AXPAXLIs prospects in wet AMD after competitor EyePoints trial setback. Some traders see fewer competitive threats and emphasize AXPAXLIs potential durability, while others argue the setback could fuel broader skepticism about TKI treatments; debate also centers on the companys pending NDA submission.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Traders are focused on XEs sharp post-IPO selloff, often blaming lockup-related share supply and weakness across nuclear and AI-linked stocks; concerns about the long path to commercialization and permitting also weigh on sentiment. Some holders remain bullish on Amazons backing and future data-center power demand, while others warn the selling may continue.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDAs clearance to expand Alpha Taus U.S. REGAIN recurrent-glioblastoma trial from 10 to 20 patients is drawing attention, alongside expectations for additional clinical data at the SNO meeting. Traders are broadly optimistic about the growing catalyst pipeline, while the early GBM results come from a very small cohort; completion of enrollment in the pancreatic IMPACT study is also contributing to the discussion.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results are drawing attention after wider mortgage spreads drove a sharp decline in book value and a reported loss, while earnings fell short of covering the monthly dividend. Traders are debating dividend sustainability and added risk from higher leverage, though some view the losses as largely unrealized and continue to favor the income stream.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

A broad biotech selloff, attributed by traders to rising-rate concerns, risk-off positioning and rotation away from smaller biotech stocks, is weighing on XBI. The community is split between expecting further weakness and viewing the sharp pullback as an oversold buying opportunity, with potential M&A and upcoming clinical catalysts cited as reasons for optimism.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp, high-volume rebound after a steep AI-infrastructure selloff has drawn attention to WULF, with traders highlighting CEO Paul Pragers CNBC defense of its power-and-data-center leasing model, which avoids owning rapidly depreciating chips, and bullish Morgan Stanley commentary. The community is split between viewing the move as a possible reversal and worrying that financing costs, leverage, and broader sector weakness could bring renewed selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firms Securities Investigation Following 37.3% Share Drop

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (uniQure or the Company) (NASDAQ: QURE) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other unlawful business...

uniQure Plunges on Additional Data From Huntington's Disease Study

QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty. 

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)PR NewswireNEW YORK, Sept. 29, 2026uniQure's four-year AMT-130 Huntington's disease benefit...

QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data  

Equity

uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years. 


QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (UniQure or the Company) (NASDAQ: QURE) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on...

QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know

uniQure’s Ifezuntirgene slowed disease progression by 80% on a measure combining movement, thinking and daily function.


Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch 

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next 

Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QURE Submits Application for Gene Therapy for Huntington's Disease

QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

Bearish Sentiment

<ul class="summary-bullets"><li>UniQure filed an application with the FDA seeking approval for the gene therapy earlier this month.&nbsp;</li><li>Stifel said the overall case for AMT-130 looks unchanged heading into regulatory review.</li><li>Wells Fargo argued the four-year composite reading is a secondary measure distorted by dropouts in the external control group and does not undo the three-year result that underpins the filing.&nbsp;</li></ul> Shares of uniQure (<a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a>) collapsed 37% on Tuesday after four-year results from its Huntington’s gene therapy study missed a key statistical test, even as the company said the treatment still slowed decline, and analysts largely kept bullish ratings.Shares clocked their worst day since Nov. 2025 and closed Monday at $24.51, down from Monday’s closing price of $39.11.<h2 class="st-heading-2">What The <a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a> Trial Showed</h2>uniQure said its one-time gene therapy, AMT-130, continued to slow Huntington’s disease in ongoing early- and mid-stage studies. Huntington’s is an inherited brain disorder with no approved treatment that changes how the disease unfolds.Patients received a single dose delivered into the brain. Their results were compared with similar patients from a large long-term disease database, not a conventional placebo group.The U.S. application filed earlier this month rests on three-year results. That snapshot covers 15 high-dose patients. On a broad score of thinking, movement and daily function, decline slowed by 80% following treatment. On a narrower score of everyday independence, it slowed decline by 67%. The company said both differences stood out in its analysis. The treatment was generally well tolerated. Most side effects were linked to the brain surgery used to deliver the therapy and later resolved.The first four-year look, limited to 12 high-dose patients, was weaker. Slowing on the broad score fell to 44% and missed statistical significance. Everyday independence still showed a 61% slowing. uniQure said the later comparison likely understated the benefit because many people in the control database dropped out, leaving a group that appeared to decline more slowly than typical Huntington’s patients.<h2 class="st-heading-2">Analysts Stay Constructive On <a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a></h2>Stifel kept a Buy rating. It said the expanded three-year results still look robust and that four-year data continue to support a drug effect, even if the composite score faded. Daily-function results held up, the firm said, and the overall case looks unchanged heading into regulatory review.H.C. Wainwright also kept a Buy rating and an $80 target. It called the broader three-year update encouraging but said the four-year composite result complicates the durability argument. Those later results were not part of the filed application. The next milestone, the firm said, is whether the FDA accepts the filing for review.RBC Capital’s Luca Issi called the package mixed. The four-year composite miss and the apparent fade from year three were not what the firm wanted to see, though daily-function benefit stayed consistent and comparisons across time points are imperfect. RBC still thinks approval is possible in a disease with a sharply elevated suicide risk and said the stock move looks overdone. It kept an Outperform rating.Wells Fargo reiterated an Overweight rating and a $75 target. It argued the four-year composite reading is a secondary measure distorted by dropouts in the external control group and does not undo the three-year result that underpins the filing. The firm called the selloff out of proportion and said the weakness may create a buying opportunity before the next regulatory update.<h2 class="st-heading-2">How Did <a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a> Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$QURE" data-symbol-id="QURE" href="https://stocktwits.com/symbol/QURE" target="_blank">QURE</a> stock stayed within the extremely bullish territory over the past 24 hours, while message volume rose from high to extremely high levels.A Stocktwits user opined that despite the data announced on Tuesday, AMT-130 is “still the best hope for Huntington.”<stembedurl>https://stocktwits.com/Cap_00/message/665371669</stembedurl>Another dismissed the selloff on Tuesday as an overreaction.<stembedurl>https://stocktwits.com/Rixhard66774433/message/665358355</stembedurl><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> has gained 2% year-to-date after Tuesday’s selloff.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/be-stock-recovers-after-monday-slide-on-analyst-support-peers-fcel-plug-edge-higher/cZMZQn3RBWL">BE Stock Recovers After Monday Slide On Analyst Support: Peers FCEL, PLUG Edge Higher</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years. 

QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data

uniQure NV

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$21.78
Prev Close	$22.52
Open	$22.50
Dividend Yield	0.00%
50-Day Moving Average	$39.30
Beta	1.36
Avg. Volume	3.07M
PE Ratio	-5.38

52-Week High	$71.50
52-Week Low	$8.73
Market Capitalization	$1.51B
EPS (Annual)	-$3.46
Price to Book	4.66
Revenue Per Employee	$72,841.63

Feed

News

Sentiment

Earnings

Fundamentals

Info

QURE Fundamentals